parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in b-cells	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 14022

POU2F2 in microglia, braak-0.14 (p 0.718) → +0.37 (p 0.329)receipt 14029
POU2F2 in dopamine neurons, braak-0.32 (p 0.407) → -0.30 (p 0.436)receipt 14030

receipt 14030: POU2F2 in dopamine neurons, braak

power: full sample -0.29 (p 0.250, n 18), 95% CI -0.66 to +0.21. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.31 (p 0.218, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.46 (p 0.057, n 18). could be the mix.
skeptic: leave-one-out range -0.41 to -0.19, sign flips 0; without severely affected donors -0.29 (p 0.250, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for POU2F2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 14029: POU2F2 in microglia, braak

power: full sample +0.04 (p 0.881, n 18), 95% CI -0.44 to +0.50. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.05 (p 0.840, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.07 (p 0.774, n 18). could be the mix.
skeptic: leave-one-out range -0.10 to +0.14, sign flips 4; without severely affected donors +0.04 (p 0.881, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for POU2F2 in microglia.

case closed: nothing better to follow up.

loading the receipts